



21 February 2018

ASX Limited

SomnoMed Limited – Successful completion of Institutional Entitlement Offer

SomnoMed is today pleased to announce the successful completion of the Institutional Entitlement Offer. Approximately 1.97 million New Shares will be issued to successful applicants under the Institutional Entitlement Offer at an issue price of \$3.00 per New Share (Offer Price), raising approximately \$5.9 million.

The Institutional Entitlement Offer received strong support from existing shareholders and the shortfall, comprised of the entitlements not taken up by eligible institutional shareholders along with the entitlements of ineligible institutional shareholders will be taken up by TDM Asset Management Pty Ltd and other major existing shareholders.

As a result of the successful completion of the Institutional Entitlement Offer, SomnoMed shares will recommence normal trading on an ex-entitlement basis from the opening of the market on 21 February 2018.

Under the Retail Entitlement Offer, eligible retail shareholders will be able to subscribe for 1 new share for every 17 existing shares held at 7.00pm (Sydney time) on 21 February 2018 at the Offer Price. Eligible retail shareholders will receive an Information Booklet including a personalised Entitlement and Acceptance Form which will provide further details of how to participate in the Retail Entitlement Offer.

A copy of the Information Booklet will be lodged today with ASX and is due to be despatched (along with the Entitlement and Acceptance Form) on 26 February 2018. The Retail Entitlement Offer will open on 26 February 2018 and close at 5.00pm (Sydney time) on 15 March 2018.

TDM Asset Management Pty Ltd, along with other major existing shareholders, have committed to subscribe for any shortfall under the Retail Entitlement Offer.

Terry Flitcroft
Company Secretary
SomnoMed Limited

About SomnoMed

SomnoMed is a public company providing diagnostic and treatment solutions for Sleep-related Breathing Disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for obstructive sleep apnea. SomnoDent® is the most comfortable and effective design and treatment solution for almost 400,000 patients in 28 countries. For additional information, visit SomnoMed at <http://www.somnomed.com.au>